{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T13:12:25Z","timestamp":1795007545705,"version":"4.9.1"},"reference-count":216,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T00:00:00Z","timestamp":1651708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T00:00:00Z","timestamp":1651708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1038\/s41584-022-00776-6","type":"journal-article","created":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T14:04:11Z","timestamp":1651759451000},"page":"311-325","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":165,"title":["Psoriatic arthritis from a mechanistic perspective"],"prefix":"10.1038","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8740-9615","authenticated-orcid":false,"given":"Georg","family":"Schett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Proton","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Ritchlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4449-8501","authenticated-orcid":false,"given":"Iain B.","family":"McInnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7468-974X","authenticated-orcid":false,"given":"Dirk","family":"Elewaut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose U.","family":"Scher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,5]]},"reference":[{"key":"776_CR1","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.3899\/jrheum.190054","volume":"46","author":"E Lubrano","year":"2019","unstructured":"Lubrano, E., Scriffignano, S. & Perrotta, F. M. Psoriatic arthritis, psoriatic disease, or psoriatic syndrome? J. Rheumatol. 46, 1428\u20131430 (2019).","journal-title":"J. Rheumatol."},{"key":"776_CR2","doi-asserted-by":"publisher","first-page":"941","DOI":"10.3899\/jrheum.200051","volume":"47","author":"R Scarpa","year":"2020","unstructured":"Scarpa, R. Psoriatic syndrome or psoriatic disease? J. Rheumatol. 47, 941 (2020).","journal-title":"J. Rheumatol."},{"key":"776_CR3","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3899\/jrheum.200127","volume":"96","author":"YY Leung","year":"2020","unstructured":"Leung, Y. Y. et al. The GRAPPA-OMERACT Working Group: 4 prioritized domains for completing the core outcome measurement set for psoriatic arthritis 2019 Updates. J. Rheumatol. Suppl. 96, 46\u201349 (2020).","journal-title":"J. Rheumatol. Suppl."},{"key":"776_CR4","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/art.21972","volume":"54","author":"W Taylor","year":"2006","unstructured":"Taylor, W. et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 54, 2665\u20132673 (2006).","journal-title":"Arthritis Rheum."},{"key":"776_CR5","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1136\/ard.32.3.181","volume":"32","author":"JM Moll","year":"1973","unstructured":"Moll, J. M. & Wright, V. Familial occurrence of psoriatic arthritis. Ann. Rheum. Dis. 32, 181\u2013201 (1973).","journal-title":"Ann. Rheum. Dis."},{"key":"776_CR6","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1002\/acr.23836","volume":"72","author":"D Solmaz","year":"2020","unstructured":"Solmaz, D. et al. Impact of having family history of psoriasis or psoriatic arthritis on psoriatic disease. Arthritis Care Res. 72, 63\u201368 (2020).","journal-title":"Arthritis Care Res."},{"key":"776_CR7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2340\/00015555-2171","volume":"96","author":"AS Lonnberg","year":"2016","unstructured":"Lonnberg, A. S. et al. Genetic factors explain variation in the age at onset of psoriasis: a population-based twin study. Acta Derm. Venereol. 96, 35\u201338 (2016).","journal-title":"Acta Derm. Venereol."},{"key":"776_CR8","first-page":"7","volume":"186","author":"G Swanbeck","year":"1994","unstructured":"Swanbeck, G., Inerot, A., Martinsson, T. & Wahlstr\u00f6m, J. A population genetic study of psoriasis. Acta Derm. Venereol. Suppl. 186, 7\u20138 (1994).","journal-title":"Acta Derm. Venereol. Suppl."},{"key":"776_CR9","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1093\/rheumatology\/keh589","volume":"44","author":"A Myers","year":"2005","unstructured":"Myers, A., Kay, L. J., Lynch, S. A. & Walker, D. J. Recurrence risk for psoriasis and psoriatic arthritis within sibships. Rheumatology 44, 773\u2013776 (2005).","journal-title":"Rheumatology"},{"key":"776_CR10","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1136\/ard.2007.078428","volume":"67","author":"OB Pedersen","year":"2008","unstructured":"Pedersen, O. B., Svendsen, A. J., Ejstrup, L., Skytthe, A. & Junker, P. On the heritability of psoriatic arthritis. Disease concordance among monozygotic and dizygotic twins. Ann. Rheum. Dis. 67, 1417\u20131421 (2008).","journal-title":"Ann. Rheum. Dis."},{"key":"776_CR11","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1136\/ard.2008.089367","volume":"68","author":"V Chandran","year":"2009","unstructured":"Chandran, V. et al. Familial aggregation of psoriatic arthritis. Ann. Rheum. Dis. 68, 664\u2013667 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"776_CR12","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1038\/ng.3941","volume":"49","author":"J Yang","year":"2017","unstructured":"Yang, J., Zeng, J., Goddard, M. E., Wray, N. R. & Visscher, P. M. Concepts, estimation and interpretation of SNP-based heritability. Nat. Genet. 49, 1304\u20131310 (2017).","journal-title":"Nat. Genet."},{"key":"776_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-61981-5","volume":"10","author":"Q Li","year":"2020","unstructured":"Li, Q. et al. Quantifying differences in heritability among psoriatic arthritis (PsA), cutaneous psoriasis (PsC) and psoriasis vulgaris (PsV). Sci. Rep. 10, 4925 (2020).","journal-title":"Sci. Rep."},{"key":"776_CR14","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1002\/acr.20627","volume":"63","author":"JA Husted","year":"2011","unstructured":"Husted, J. A. et al. Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison with patients with psoriasis. Arthritis Care Res. 63, 1729\u20131735 (2011).","journal-title":"Arthritis Care Res."},{"key":"776_CR15","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1086\/503821","volume":"78","author":"RP Nair","year":"2006","unstructured":"Nair, R. P. et al. Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. Am. J. Hum. Genet. 78, 827\u2013851 (2006).","journal-title":"Am. J. Hum. Genet."},{"key":"776_CR16","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1002\/art.33415","volume":"64","author":"R Winchester","year":"2012","unstructured":"Winchester, R. et al. HLA associations reveal genetic heterogeneity in psoriatic arthritis and in the psoriasis phenotype. Arthritis Rheum. 64, 1134\u20131144 (2012).","journal-title":"Arthritis Rheum."},{"key":"776_CR17","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1136\/annrheumdis-2012-201308","volume":"71","author":"L Eder","year":"2012","unstructured":"Eder, L. et al. Differential human leucocyte allele association between psoriasis and psoriatic arthritis: a family-based association study. Ann. Rheum. Dis. 71, 1361\u20131365 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"776_CR18","doi-asserted-by":"crossref","unstructured":"Winchester R., & Rahman P. in Oxford Textbook of Psoriatic Arthritis (ed Gladman D. & FitzGerald O.) 57\u201367 (Oxford University Press, 2019).","DOI":"10.1093\/med\/9780198737582.003.0006"},{"key":"776_CR19","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1136\/annrheumdis-2014-205461","volume":"75","author":"M Haroon","year":"2016","unstructured":"Haroon, M., Winchester, R., Giles, J. T., Heffernan, E. & FitzGerald, O. Certain class I HLA alleles and haplotypes implicated in susceptibility play a role in determining specific features of the psoriatic arthritis phenotype. Ann. Rheum. Dis. 75, 155\u2013162 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"776_CR20","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13075-015-0640-3","volume":"17","author":"O FitzGerald","year":"2015","unstructured":"FitzGerald, O., Haroon, M., Giles, J. T. & Winchester, R. Concepts of pathogenesis in psoriatic arthritis: genotype determines clinical phenotype. Arthritis Res. Ther. 17, 115 (2015).","journal-title":"Arthritis Res. Ther."},{"key":"776_CR21","first-page":"675","volume":"22","author":"DD Gladman","year":"1995","unstructured":"Gladman, D. D., Farewell, V. T. & Nadeau, C. Clinical indicators of progression in psoriatic arthritis: multivariate relative risk model. J. Rheumatol. 22, 675\u2013679 (1995).","journal-title":"J. Rheumatol."},{"key":"776_CR22","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1016\/j.humimm.2013.07.014","volume":"74","author":"V Chandran","year":"2013","unstructured":"Chandran, V. et al. Human leukocyte antigen alleles and susceptibility to psoriatic arthritis. Hum. Immunol. 74, 1333\u20131338 (2013).","journal-title":"Hum. Immunol."},{"key":"776_CR23","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.ajhg.2014.07.002","volume":"95","author":"Y Okada","year":"2014","unstructured":"Okada, Y. et al. Fine mapping major histocompatibility complex associations in psoriasis and its clinical subtypes. Am. J. Hum. Genet. 95, 162\u2013172 (2014).","journal-title":"Am. J. Hum. Genet."},{"key":"776_CR24","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1136\/annrheumdis-2014-207187","volume":"74","author":"J Bowes","year":"2015","unstructured":"Bowes, J. et al. PTPN22 is associated with susceptibility to psoriatic arthritis but not psoriasis: evidence for a further PsA-specific risk locus. Ann. Rheum. Dis. 74, 1882\u20131885 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"776_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18513-6","volume":"11","author":"F Pencava","year":"2020","unstructured":"Pencava, F. et al. Single-cell sequencing reveals clonal expansions of pro-inflammatory synovial CD8 T cells expressing tissue-homing receptors in psoriatic arthritis. Nat. Commun. 11, 4767 (2020).","journal-title":"Nat. Commun."},{"key":"776_CR26","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1002\/art.41156","volume":"72","author":"KJA Steel","year":"2020","unstructured":"Steel, K. J. A. et al. Polyfunctional, proinflammatory, tissue-resident memory phenotype and function of synovial interleukin-17A+CD8+ T cells in psoriatic arthritis. Arthritis Rheumatol. 72, 435\u2013447 (2020).","journal-title":"Arthritis Rheumatol."},{"key":"776_CR27","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1126\/science.8178173","volume":"264","author":"J Tomfohrde","year":"1994","unstructured":"Tomfohrde, J. et al. Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17q. Science 264, 1141\u20131145 (1994).","journal-title":"Science"},{"key":"776_CR28","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.ajhg.2012.03.012","volume":"90","author":"CT Jordan","year":"2012","unstructured":"Jordan, C. T. et al. PSORS2 is due to mutations in CARD14. Am. J. Hum. Genet. 90, 784\u2013795 (2012).","journal-title":"Am. J. Hum. Genet."},{"key":"776_CR29","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1056\/NEJMoa1013068","volume":"365","author":"S Marrakchi","year":"2011","unstructured":"Marrakchi, S. et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N. Engl. J. Med. 365, 620\u2013628 (2011).","journal-title":"N. Engl. J. Med."},{"key":"776_CR30","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.ajhg.2011.07.022","volume":"89","author":"A Onoufriadis","year":"2011","unstructured":"Onoufriadis, A. et al. Mutations in IL36RN\/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. Am. J. Hum. Genet. 89, 432\u2013437 (2011).","journal-title":"Am. J. Hum. Genet."},{"key":"776_CR31","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.ajhg.2015.10.019","volume":"97","author":"PE Stuart","year":"2015","unstructured":"Stuart, P. E. et al. Genome-wide association analysis of psoriatic arthritis and cutaneous psoriasis reveals differences in their genetic architecture. Am. J. Hum. Genet. 97, 816\u2013836 (2015).","journal-title":"Am. J. Hum. Genet."},{"key":"776_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7046","volume":"6","author":"J Bowes","year":"2015","unstructured":"Bowes, J. et al. Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis. Nat. Commun. 6, 6046 (2015).","journal-title":"Nat. Commun."},{"key":"776_CR33","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/ng.689","volume":"42","author":"E Ellinghaus","year":"2010","unstructured":"Ellinghaus, E. et al. Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2. Nat. Genet. 42, 991\u2013995 (2010).","journal-title":"Nat. Genet."},{"key":"776_CR34","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s11926-020-0886-x","volume":"22","author":"S Rahmati","year":"2020","unstructured":"Rahmati, S., Tsoi, L., O\u2019Rielly, D. D., Chandran, V. & Rahman, P. Complexities in genetics of psoriatic arthritis. Curr. Rheumatol. Rep. 22, 10 (2020).","journal-title":"Curr. Rheumatol. Rep."},{"key":"776_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06672-6","volume":"9","author":"MT Patrick","year":"2018","unstructured":"Patrick, M. T. et al. Genetic signature to provide robust risk assessment of psoriatic arthritis development in psoriasis patients. Nat. Commun. 9, 4178 (2018).","journal-title":"Nat. Commun."},{"key":"776_CR36","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41588-020-00763-1","volume":"53","author":"A Kurilshikov","year":"2021","unstructured":"Kurilshikov, A. et al. Large-scale association analyses identify host factors influencing human gut microbiome composition. Nat. Genet. 53, 156\u2013165 (2021).","journal-title":"Nat. Genet."},{"key":"776_CR37","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1002\/art.40183","volume":"69","author":"M Asquith","year":"2017","unstructured":"Asquith, M. et al. Intestinal metabolites are profoundly altered in the context of HLA-B27 expression and functionally modulate disease in a rat model of spondyloarthritis. Arthritis Rheumatol. 69, 1984\u20131995 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"776_CR38","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1002\/art.41018","volume":"71","author":"T Gill","year":"2019","unstructured":"Gill, T. et al. Novel inter-omic analysis reveals relationships between diverse gut microbiota and host immune dysregulation in HLA-B27-induced experimental spondyloarthritis. Arthritis Rheumatol. 71, 1849\u20131857 (2019).","journal-title":"Arthritis Rheumatol."},{"key":"776_CR39","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1136\/annrheumdis-2019-215763","volume":"79","author":"J Yin","year":"2020","unstructured":"Yin, J. et al. Shotgun metagenomics reveals an enrichment of potentially cross-reactive bacterial epitopes in ankylosing spondylitis patients, as well as the effects of TNFi therapy upon microbiome composition. Ann. Rheum. Dis. 79, 132\u2013140 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"776_CR40","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/art.40359","volume":"70","author":"J Manasson","year":"2018","unstructured":"Manasson, J. et al. Gut microbiota perturbations in reactive arthritis and postinfectious spondyloarthritis. Arthritis Rheumatol. 70, 242\u2013254 (2018).","journal-title":"Arthritis Rheumatol."},{"key":"776_CR41","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1136\/annrheumdis-2019-215743","volume":"79","author":"T Kishikawa","year":"2020","unstructured":"Kishikawa, T. et al. Metagenome-wide association study of gut microbiome revealed novel aetiology of rheumatoid arthritis in the Japanese population. Ann. Rheum. Dis. 79, 103\u2013111 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"776_CR42","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.01202","volume":"2","author":"J Scher","year":"2013","unstructured":"Scher, J. et al. Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis. eLife 2, e01202 (2013).","journal-title":"eLife"},{"key":"776_CR43","doi-asserted-by":"publisher","first-page":"j5145","DOI":"10.1136\/bmj.j5145","volume":"360","author":"JC Clemente","year":"2018","unstructured":"Clemente, J. C., Manasson, J. & Scher, J. U. The role of the gut microbiome in systemic inflammatory disease. BMJ 360, j5145 (2018).","journal-title":"BMJ"},{"key":"776_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s40168-017-0267-5","volume":"5","author":"D Kim","year":"2017","unstructured":"Kim, D. et al. Optimizing methods and dodging pitfalls in microbiome research. Microbiome 5, 52 (2017).","journal-title":"Microbiome"},{"key":"776_CR45","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/art.39259","volume":"68","author":"JU Scher","year":"2016","unstructured":"Scher, J. U., Littman, D. R. & Abramson, S. B. Microbiome in inflammatory arthritis and human rheumatic diseases. Arthritis Rheumatol. 68, 35\u201345 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"776_CR46","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nrrheum.2016.68","volume":"12","author":"S Abdollahi-Roodsaz","year":"2016","unstructured":"Abdollahi-Roodsaz, S., Abramson, S. B. & Scher, J. U. The metabolic role of the gut microbiota in health and rheumatic disease: mechanisms and interventions. Nat. Rev. Rheumatol. 12, 446\u2013455 (2016).","journal-title":"Nat. Rev. Rheumatol."},{"key":"776_CR47","first-page":"5","volume":"12","author":"V Aguiar-Pulido","year":"2016","unstructured":"Aguiar-Pulido, V. et al. Metagenomics, metatranscriptomics, and metabolomics approaches for microbiome analysis. Evol. Bioinform. Online 12, 5\u201316 (2016).","journal-title":"Evol. Bioinform. Online"},{"key":"776_CR48","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/j.1574-6941.2011.01284.x","volume":"80","author":"A Siggins","year":"2012","unstructured":"Siggins, A., Gunnigle, E. & Abram, F. Exploring mixed microbial community functioning: recent advances in metaproteomics. FEMS Microbiol. Ecol. 80, 265\u2013280 (2012).","journal-title":"FEMS Microbiol. Ecol."},{"key":"776_CR49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0105684","volume":"9","author":"P Lin","year":"2014","unstructured":"Lin, P. et al. HLA-B27 and human beta2-microglobulin affect the gut microbiota of transgenic rats. PLoS One 9, e105684 (2014).","journal-title":"PLoS One"},{"key":"776_CR50","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1002\/art.39681","volume":"68","author":"MJ Asquith","year":"2016","unstructured":"Asquith, M. J. et al. Perturbed mucosal immunity and dysbiosis accompany clinical disease in a rat model of spondyloarthritis. Arthritis Rheumatol. 68, 2151\u20132162 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"776_CR51","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1084\/jem.180.6.2359","volume":"180","author":"JD Taurog","year":"1994","unstructured":"Taurog, J. D. et al. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J. Exp. Med. 180, 2359\u20132364 (1994).","journal-title":"J. Exp. Med."},{"key":"776_CR52","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1084\/jem.20041758","volume":"201","author":"H Yoshitomi","year":"2005","unstructured":"Yoshitomi, H. et al. A role for fungal {beta}-glucans and their receptor Dectin-1 in the induction of autoimmune arthritis in genetically susceptible mice. J. Exp. Med. 201, 949\u20139608 (2005).","journal-title":"J. Exp. Med."},{"key":"776_CR53","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1002\/art.38892","volume":"67","author":"JU Scher","year":"2015","unstructured":"Scher, J. U. et al. Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease. Arthritis Rheumatol. 67, 128\u2013139 (2015).","journal-title":"Arthritis Rheumatol."},{"key":"776_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-22125-y","volume":"8","author":"FM Codo\u00f1er","year":"2018","unstructured":"Codo\u00f1er, F. M. et al. Gut microbial composition in patients with psoriasis. Sci. Rep. 8, 3812 (2018).","journal-title":"Sci. Rep."},{"key":"776_CR55","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1111\/1346-8138.14933","volume":"46","author":"J Shapiro","year":"2019","unstructured":"Shapiro, J. et al. Psoriatic patients have a distinct structural and functional fecal microbiota compared with controls. J. Dermatol. 46, 595\u2013603 (2019).","journal-title":"J. Dermatol."},{"key":"776_CR56","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1111\/exd.13786","volume":"27","author":"YJ Chen","year":"2018","unstructured":"Chen, Y. J. et al. Intestinal microbiota profiling and predicted metabolic dysregulation in psoriasis patients. Exp. Dermatol. 27, 1336\u20131343 (2018).","journal-title":"Exp. Dermatol."},{"key":"776_CR57","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1002\/art.24389","volume":"60","author":"F Ciccia","year":"2009","unstructured":"Ciccia, F. et al. Overexpression of interleukin-23, but not interleukin-17, as an immunologic signature of subclinical intestinal inflammation in ankylosing spondylitis. Arthritis Rheum. 60, 955\u2013965 (2009).","journal-title":"Arthritis Rheum."},{"key":"776_CR58","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1002\/art.33507","volume":"64","author":"TJ Kenna","year":"2012","unstructured":"Kenna, T. J. et al. Enrichment of circulating interleukin-17-secreting interleukin-23 receptor-positive \u03b3\/\u03b4 T cells in patients with active ankylosing spondylitis. Arthritis Rheum. 64, 1420\u20131429 (2012).","journal-title":"Arthritis Rheum."},{"key":"776_CR59","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1136\/annrheumdis-2015-208902","volume":"75","author":"E Gracey","year":"2016","unstructured":"Gracey, E. et al. IL-7 primes IL-17 in mucosal-associated invariant T (MAIT) cells, which contribute to the Th17-axis in ankylosing spondylitis. Ann. Rheum. Dis. 75, 2124\u20132132 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"776_CR60","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.4049\/jimmunol.1700596","volume":"200","author":"A Soare","year":"2018","unstructured":"Soare, A. et al. Homeostasis of innate lymphoid cells is imbalanced in psoriatic arthritis. J. Immunol. 200, 1249\u20131254 (2018).","journal-title":"J. Immunol."},{"key":"776_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9424","volume":"6","author":"P Zanvit","year":"2015","unstructured":"Zanvit, P. et al. Antibiotics in neonatal life increase murine susceptibility to experimental psoriasis. Nat. Commun. 6, 8424 (2015).","journal-title":"Nat. Commun."},{"key":"776_CR62","doi-asserted-by":"publisher","first-page":"236","DOI":"10.3389\/fmicb.2019.00236","volume":"10","author":"Z Stehlikova","year":"2019","unstructured":"Stehlikova, Z. et al. Crucial role of microbiota in experimental psoriasis revealed by a gnotobiotic mouse model front microbiol. Front Microbiol. 10, 236 (2019).","journal-title":"Front Microbiol."},{"key":"776_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/s40168-018-0533-1","volume":"6","author":"HW Chang","year":"2018","unstructured":"Chang, H. W. et al. Alteration of the cutaneous microbiome in psoriasis and potential role in Th17 polarization. Microbiome 6, 154 (2018).","journal-title":"Microbiome"},{"key":"776_CR64","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1111\/bjd.17989","volume":"181","author":"EA Langan","year":"2019","unstructured":"Langan, E. A. et al. Combined culture and metagenomic analyses reveal significant shifts in the composition of the cutaneous microbiome in psoriasis. Br. J. Dermatol. 181, 1254\u20131264 (2019).","journal-title":"Br. J. Dermatol."},{"key":"776_CR65","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1016\/j.jid.2018.03.1501","volume":"138","author":"MA Loesche","year":"2018","unstructured":"Loesche, M. A. et al. Longitudinal study of the psoriasis-associated skin microbiome during therapy with ustekinumab in a randomized phase 3b clinical trial. J. Invest. Dermatol. 138, 1973\u20131981 (2018).","journal-title":"J. Invest. Dermatol."},{"key":"776_CR66","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1126\/science.1171700","volume":"324","author":"EA Grice","year":"2009","unstructured":"Grice, E. A. et al. Topographical and temporal diversity of the human skin microbiome. Science 324, 1190\u20131192 (2009).","journal-title":"Science"},{"key":"776_CR67","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1016\/j.chom.2021.05.011","volume":"29","author":"A Uberoi","year":"2021","unstructured":"Uberoi, A. et al. Commensal microbiota regulates skin barrier function and repair via signaling through the aryl hydrocarbon receptor. Cell Host Microbe 29, 1235\u20131248 (2021).","journal-title":"Cell Host Microbe"},{"key":"776_CR68","doi-asserted-by":"publisher","DOI":"10.1186\/s40168-018-0404-9","volume":"6","author":"JS Meisel","year":"2018","unstructured":"Meisel, J. S. et al. Commensal microbiota modulate gene expression in the skin. Microbiome 6, 20 (2018).","journal-title":"Microbiome"},{"key":"776_CR69","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1126\/science.1225152","volume":"337","author":"S Naik","year":"2012","unstructured":"Naik, S. et al. Compartmentalized control of skin immunity by resident commensals. Science 337, 1115\u20131119 (2012).","journal-title":"Science"},{"key":"776_CR70","doi-asserted-by":"publisher","first-page":"E2120","DOI":"10.1073\/pnas.1424409112","volume":"112","author":"A Bouslimani","year":"2015","unstructured":"Bouslimani, A. et al. Molecular cartography of the human skin surface in 3D. Proc. Natl Acad. Sci. USA 112, E2120\u2013E2129 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"776_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12253-y","volume":"10","author":"N Fyhrquist","year":"2019","unstructured":"Fyhrquist, N. et al. Microbe-host interplay in atopic dermatitis and psoriasis. Nat. Commun. 10, 4703 (2019).","journal-title":"Nat. Commun."},{"key":"776_CR72","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature12721","volume":"504","author":"Y Furusawa","year":"2013","unstructured":"Furusawa, Y. et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 504, 446\u2013450 (2013).","journal-title":"Nature"},{"key":"776_CR73","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1093\/ibd\/izz046","volume":"25","author":"L Chen","year":"2019","unstructured":"Chen, L. et al. Microbiota metabolite butyrate differentially regulates Th1 and Th17 cells\u2019 differentiation and function in induction of colitis. Inflamm. Bowel Dis. 25, 1450\u20131461 (2019).","journal-title":"Inflamm. Bowel Dis."},{"key":"776_CR74","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.cmet.2020.03.003","volume":"31","author":"EC Rosser","year":"2020","unstructured":"Rosser, E. C. et al. Microbiota-derived metabolites suppress arthritis by amplifying aryl-hydrocarbon receptor activation in regulatory B cells. Cell Metab. 31, 837\u2013851 (2020).","journal-title":"Cell Metab."},{"key":"776_CR75","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.3389\/fimmu.2018.01525","volume":"9","author":"DS Kim","year":"2018","unstructured":"Kim, D. S. et al. Attenuation of rheumatoid inflammation by sodium butyrate through reciprocal targeting of HDAC2 in osteoclasts and HDAC8 in T cells. Front. Immunol. 9, 1525 (2018).","journal-title":"Front. Immunol."},{"key":"776_CR76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-017-02490-4","volume":"9","author":"S Lucas","year":"2018","unstructured":"Lucas, S. et al. Short-chain fatty acids regulate systemic bone mass and protect from pathological bone loss. Nat. Commun. 9, 1\u201310 (2018).","journal-title":"Nat. Commun."},{"key":"776_CR77","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.3390\/nu12103207","volume":"12","author":"K D\u00fcrholz","year":"2020","unstructured":"D\u00fcrholz, K. et al. Dietary short-term fiber interventions in arthritis patients increase systemic SCFA levels and regulate inflammation. Nutrients 12, 3207 (2020).","journal-title":"Nutrients"},{"key":"776_CR78","unstructured":"Fardina Malik, J. M. et al. in American College of Rheumatology 2018 ACR\/ARHP Annual Meeting Abstract Number 2058 (Wiley, 2018)."},{"key":"776_CR79","first-page":"CD011571","volume":"3","author":"G Dupire","year":"2019","unstructured":"Dupire, G., Droitcourt, C., Hughes, C. & Le Cleach, L. Antistreptococcal interventions for guttate and chronic plaque psoriasis. Cochrane Database Syst. Rev. 3, CD011571 (2019).","journal-title":"Cochrane Database Syst. Rev."},{"key":"776_CR80","doi-asserted-by":"publisher","first-page":"326","DOI":"10.7241\/ourd.20124.71","volume":"3","author":"M Vijayashankar","year":"2012","unstructured":"Vijayashankar, M. & Raghunath, N. Pustular psoriasis responding to probiotics \u2014 a new insight. Our Dermatol. Online 3, 326 (2012).","journal-title":"Our Dermatol. Online"},{"key":"776_CR81","doi-asserted-by":"publisher","first-page":"3496","DOI":"10.4103\/jfmpc.jfmpc_709_19","volume":"8","author":"DI Alesa","year":"2019","unstructured":"Alesa, D. I. et al. The role of gut microbiome in the pathogenesis of psoriasis and the therapeutic effects of probiotics. J. Fam. Med. Prim. Care 8, 3496\u20133503 (2019).","journal-title":"J. Fam. Med. Prim. Care"},{"key":"776_CR82","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1002\/acr2.11143","volume":"2","author":"M Grinnell","year":"2020","unstructured":"Grinnell, M., Ogdie, A., Wipfler, K. & Michaud, K. Probiotic use and psoriatic arthritis disease activity. ACR Open. Rheumatol. 2, 330\u2013334 (2020).","journal-title":"ACR Open. Rheumatol."},{"key":"776_CR83","first-page":"359","volume":"15","author":"VN Saxena","year":"2005","unstructured":"Saxena, V. N. & Dogra, J. Long-term use of penicillin for the treatment of chronic plaque psoriasis. Eur. J. Dermatol. 15, 359\u2013362 (2005).","journal-title":"Eur. J. Dermatol."},{"key":"776_CR84","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-019231","volume":"8","author":"MS Kragsnaes","year":"2018","unstructured":"Kragsnaes, M. S. et al. Efficacy and safety of faecal microbiota transplantation in patients with psoriatic arthritis: protocol for a 6-month, double-blind, randomised, placebo-controlled trial. BMJ Open 8, e019231 (2018).","journal-title":"BMJ Open"},{"key":"776_CR85","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1136\/annrheumdis-2020-219511","volume":"80","author":"MS Kragsnaes","year":"2021","unstructured":"Kragsnaes, M. S. et al. Safety and efficacy of faecal microbiota transplantation for active peripheral psoriatic arthritis: an exploratory randomised placebo-controlled trial. Ann. Rheum. Dis. 80, 1158\u20131167 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"776_CR86","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220910","author":"DG McGonagle","year":"2021","unstructured":"McGonagle, D. G., Bridgewood, C. & Marzo-Ortega, H. Correspondence on \u2018Safety and efficacy of faecal microbiota transplantation for active peripheral psoriatic arthritis: an exploratory randomised placebo-controlled trial. Ann. Rheum. Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220910 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"776_CR87","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41584-020-0395-3","volume":"16","author":"JU Scher","year":"2020","unstructured":"Scher, J. U., Nayak, R. R., Ubeda, C., Turnbaugh, P. J. & Abramson, S. B. Pharmacomicrobiomics in inflammatory arthritis: gut microbiome as modulator of therapeutic response. Nat. Rev. Rheumatol. 16, 282\u2013292 (2020).","journal-title":"Nat. Rev. Rheumatol."},{"key":"776_CR88","doi-asserted-by":"publisher","first-page":"182","DOI":"10.2174\/187569210792246326","volume":"8","author":"MR Rizkallah","year":"2010","unstructured":"Rizkallah, M. R., Saad, R. & Aziz, R. K. The Human Microbiome Project, personalized medicine and the birth of pharmacomicrobiomics. Curr. Pharmacogenomics Person. Med. 8, 182\u2013193 (2010).","journal-title":"Curr. Pharmacogenomics Person. Med."},{"key":"776_CR89","first-page":"555","volume":"181","author":"MA Peppercorn","year":"1972","unstructured":"Peppercorn, M. A. & Goldman, P. The role of intestinal bacteria in the metabolism of salicylazosulfapyridine. J. Pharmacol. Exp. Ther. 181, 555\u2013562 (1972).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"776_CR90","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1126\/science.166.3907.887","volume":"166","author":"DS Zaharko","year":"1969","unstructured":"Zaharko, D. S., Bruckner, H. & Oliverio, V. T. Antibiotics alter methotrexate metabolism and excretion. Science 166, 887\u2013888 (1969).","journal-title":"Science"},{"key":"776_CR91","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/0006-2952(72)90125-6","volume":"21","author":"DM Valerino","year":"1972","unstructured":"Valerino, D. M., Johns, D. G., Zaharko, D. S. & Oliverio, V. T. Studies of the metabolism of methotrexate by intestinal flora. I. Identification and study of biological properties of the metabolite 4-amino-4-deoxy-N 10-methylpteroic acid. Biochem. Pharmacol. 21, 821\u2013831 (1972).","journal-title":"Biochem. Pharmacol."},{"key":"776_CR92","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1002\/art.41622","volume":"73","author":"A Artacho","year":"2021","unstructured":"Artacho, A. et al. The pre-treatment gut microbiome is associated with lack of response to methotrexate in new onset rheumatoid arthritis. Arthritis Rheumatol. 73, 931\u2013942 (2021).","journal-title":"Arthritis Rheumatol."},{"key":"776_CR93","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.chom.2020.12.008","volume":"29","author":"RR Nayak","year":"2021","unstructured":"Nayak, R. R. et al. Methotrexate impacts conserved pathways in diverse human gut bacteria leading to decreased host immune activation. Cell Host Microbe 29, 362\u2013377 (2021).","journal-title":"Cell Host Microbe"},{"key":"776_CR94","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-23571-4","volume":"8","author":"T Bazin","year":"2018","unstructured":"Bazin, T. et al. Microbiota composition may predict anti-TNF alpha response in spondyloarthritis patients: an exploratory study. Sci. Rep. 8, 5446 (2018).","journal-title":"Sci. Rep."},{"key":"776_CR95","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1002\/art.41169","volume":"72","author":"J Manasson","year":"2020","unstructured":"Manasson, J. et al. IL-17 inhibition in spondyloarthritis associates with subclinical gut microbiome perturbations and a distinctive IL-25-driven intestinal inflammation. Arthritis Rheumatol. 72, 645\u2013657 (2020).","journal-title":"Arthritis Rheumatol."},{"key":"776_CR96","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1007\/s40261-019-00849-7","volume":"39","author":"NL Yeh","year":"2019","unstructured":"Yeh, N. L., Hsu, C. Y., Tsai, T. F. & Chiu, H. Y. Gut microbiome in psoriasis is perturbed differently during secukinumab and ustekinumab therapy and associated with response to treatment. Clin. Drug Investig. 39, 1195\u20131203 (2019).","journal-title":"Clin. Drug Investig."},{"key":"776_CR97","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1038\/s41467-018-04450-y","volume":"9","author":"P Hegde","year":"2018","unstructured":"Hegde, P. et al. Mucosal-associated invariant T cells area profibrogenic immune cell population in the liver. Nat. Commun. 9, 2146 (2018).","journal-title":"Nat. Commun."},{"key":"776_CR98","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1001\/archinte.167.15.1670","volume":"167","author":"AR Setty","year":"2007","unstructured":"Setty, A. R., Curhan, G. & Choi, H. K. Obesity, waist circumference, weight change, and the risk of psoriasis in women: nurses\u2019 health study II. Arch. Intern. Med. 167, 1670\u20131675 (2007).","journal-title":"Arch. Intern. Med."},{"key":"776_CR99","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/bjd.16885","volume":"180","author":"I Snekvik","year":"2019","unstructured":"Snekvik, I., Nilsen, T. I. L., Romundstad, P. R. & Saunes, M. Metabolic syndrome and risk of incident psoriasis: prospective data from the HUNT Study, Norway. Br. J. Dermatol. 180, 94\u201399 (2019).","journal-title":"Br. J. Dermatol."},{"key":"776_CR100","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002739","volume":"16","author":"A Budu-Aggrey","year":"2019","unstructured":"Budu-Aggrey, A. et al. Evidence of a causal relationship between body mass index and psoriasis: a Mendelian randomization study. PLoS Med. 16, e1002739 (2019).","journal-title":"PLoS Med."},{"key":"776_CR101","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.jaad.2008.10.062","volume":"60","author":"M Icen","year":"2009","unstructured":"Icen, M. et al. Trends in incidence of adult-onset psoriasis over three decades: a population-based study. J. Am. Acad. Dermatol. 60, 394\u2013401 (2009).","journal-title":"J. Am. Acad. Dermatol."},{"key":"776_CR102","volume":"10","author":"HA Alotaibi","year":"2018","unstructured":"Alotaibi, H. A. Effects of weight loss on psoriasis: a review of clinical trials. Cureus 10, e3491 (2018).","journal-title":"Cureus"},{"key":"776_CR103","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13075-019-1810-5","volume":"21","author":"E Klingberg","year":"2019","unstructured":"Klingberg, E. et al. Weight loss improves disease activity in patients with psoriatic arthritis and obesity: an interventional study. Arthritis Res. Ther. 21, 17 (2019).","journal-title":"Arthritis Res. Ther."},{"key":"776_CR104","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1001\/jamasurg.2016.4610","volume":"152","author":"A Egeberg","year":"2017","unstructured":"Egeberg, A. et al. Incidence and prognosis of psoriasis and psoriatic arthritis in patients undergoing bariatric surgery. JAMA Surg. 152, 344\u2013349 (2017).","journal-title":"JAMA Surg."},{"key":"776_CR105","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.cell.2013.12.012","volume":"156","author":"ED Rosen","year":"2014","unstructured":"Rosen, E. D. & Spiegelman, B. M. What we talk about when we talk about fat. Cell 156, 20\u201344 (2014).","journal-title":"Cell"},{"key":"776_CR106","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/ced.12171","volume":"38","author":"KJ Zhu","year":"2013","unstructured":"Zhu, K. J. et al. Leptin levels in patients with psoriasis: a meta-analysis. Clin. Exp. Dermatol. 38, 478\u2013483 (2013).","journal-title":"Clin. Exp. Dermatol."},{"key":"776_CR107","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1136\/annrheumdis-2012-202325","volume":"72","author":"L Eder","year":"2013","unstructured":"Eder, L. et al. Serum adipokines in patients with psoriatic arthritis and psoriasis alone and their correlation with disease activity. Ann. Rheum. Dis. 72, 1956\u20131961 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"776_CR108","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.trsl.2021.08.001","volume":"239","author":"S Cheleschi","year":"2022","unstructured":"Cheleschi, S., Tenti, S., Bedogni, G. & Fioravanti, A. Circulating Mir-140 and leptin improve the accuracy of the differential diagnosis between psoriatic arthritis and rheumatoid arthritis: a case-control study. Transl. Res. 239, 18\u201331 (2022).","journal-title":"Transl. Res."},{"key":"776_CR109","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1007\/s10067-019-04619-w","volume":"38","author":"F Caso","year":"2019","unstructured":"Caso, F. et al. Pro-inflammatory adipokine profile in psoriatic arthritis: results from a cross- sectional study comparing PsA subset with evident cutaneous involvement and subset \u201csine psoriasis\u201d. Clin. Rheumatol. 38, 2547\u20132552 (2019).","journal-title":"Clin. Rheumatol."},{"key":"776_CR110","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.1093\/rheumatology\/keaa720","volume":"60","author":"E Toussirot","year":"2021","unstructured":"Toussirot, E. et al. Visceral adiposity in patients with psoriatic arthritis and psoriasis alone and its relationship with metabolic and cardiovascular risk. Rheumatology 60, 2816\u20132825 (2021).","journal-title":"Rheumatology"},{"key":"776_CR111","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/s41584-019-0256-0","volume":"15","author":"LD Ferguson","year":"2019","unstructured":"Ferguson, L. D., Siebert, S., McInnes, I. B. & Sattar, N. Cardiometabolic comorbidities in RA and PsA: lessons learned and future directions. Nat. Rev. Rheumatol. 15, 461\u2013474 (2019).","journal-title":"Nat. Rev. Rheumatol."},{"key":"776_CR112","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1016\/j.jid.2018.03.1522","volume":"138","author":"D Herbert","year":"2018","unstructured":"Herbert, D. et al. High-fat diet exacerbates early psoriatic skin inflammation independent of obesity: saturated fatty acids as key players. J. Invest. Dermatol. 138, 1999\u20132009 (2018).","journal-title":"J. Invest. Dermatol."},{"key":"776_CR113","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-14292-1","volume":"7","author":"S Nakamizo","year":"2017","unstructured":"Nakamizo, S. et al. High fat diet exacerbates murine psoriatic dermatitis by increasing the number of IL-17-producing \u03b3\u03b4 T cells. Sci. Rep. 7, 14076 (2017).","journal-title":"Sci. Rep."},{"key":"776_CR114","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.immuni.2015.04.016","volume":"42","author":"Y Zhang","year":"2015","unstructured":"Zhang, Y. et al. Epidermal fatty acid binding protein promotes skin inflammation induced by high-fat diet. Immunity 42, 953\u2013964 (2015).","journal-title":"Immunity"},{"key":"776_CR115","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.cell.2017.12.013","volume":"172","author":"A Christ","year":"2018","unstructured":"Christ, A. et al. Western diet triggers NLRP3-dependent innate immune reprogramming. Cell 172, 162\u2013175 (2018).","journal-title":"Cell"},{"key":"776_CR116","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.atherosclerosis.2008.05.033","volume":"202","author":"L H\u00e5versen","year":"2009","unstructured":"H\u00e5versen, L., Danielsson, K. N., Fogelstrand, L. & Wiklund, O. Induction of proinflammatory cytokines by long-chain saturated fatty acids in human macrophages. Atherosclerosis 202, 382\u2013393 (2009).","journal-title":"Atherosclerosis"},{"key":"776_CR117","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/ni.2022","volume":"12","author":"H Wen","year":"2011","unstructured":"Wen, H. et al. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat. Immunol. 12, 408\u2013415 (2011).","journal-title":"Nat. Immunol."},{"key":"776_CR118","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.3389\/fimmu.2019.01807","volume":"10","author":"M Kunz","year":"2019","unstructured":"Kunz, M., Simon, J. C. & Saalbach, A. Psoriasis: obesity and fatty acids. Front. Immunol. 10, 1807 (2019).","journal-title":"Front. Immunol."},{"key":"776_CR119","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-88552-6","volume":"11","author":"I Olejniczak-Staruch","year":"2021","unstructured":"Olejniczak-Staruch, I. et al. AntiTNF-alpha therapy normalizes levels of lipids and adipokines in psoriatic patients in the real-life settings. Sci. Rep. 11, 9289 (2021).","journal-title":"Sci. Rep."},{"key":"776_CR120","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/nrcardio.2014.206","volume":"12","author":"M Prasad","year":"2015","unstructured":"Prasad, M. et al. Cardiorheumatology: cardiac involvement in systemic rheumatic disease. Nat. Rev. Cardiol. 12, 168 (2015).","journal-title":"Nat. Rev. Cardiol."},{"key":"776_CR121","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1001\/archdermatol.2011.119","volume":"147","author":"NN Mehta","year":"2011","unstructured":"Mehta, N. N. et al. Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET\/CT): a pilot study. Arch. Dermatol. 147, 1031\u20131039 (2011).","journal-title":"Arch. Dermatol."},{"key":"776_CR122","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/nrcardio.2009.57","volume":"6","author":"GE McKellar","year":"2009","unstructured":"McKellar, G. E., McCarey, D. W., Sattar, N. & McInnes, I. B. Role for TNF in atherosclerosis? Lessons from autoimmune disease. Nat. Rev. Cardiol. 6, 410\u2013417 (2009).","journal-title":"Nat. Rev. Cardiol."},{"key":"776_CR123","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.autrev.2017.07.009","volume":"16","author":"M Robert","year":"2017","unstructured":"Robert, M. & Miossec, P. Effects of Interleukin 17 on the cardiovascular system. Autoimmun. Rev. 16, 984\u2013991 (2017).","journal-title":"Autoimmun. Rev."},{"key":"776_CR124","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.tcm.2019.11.001","volume":"30","author":"M Aksentijevich","year":"2020","unstructured":"Aksentijevich, M., Lateef, S. S., Anzenberg, P., Dey, A. K. & Mehta, N. N. Chronic inflammation, cardiometabolic diseases and effects of treatment: psoriasis as a human model. Trends Cardiovasc. Med. 30, 472\u2013478 (2020).","journal-title":"Trends Cardiovasc. Med."},{"key":"776_CR125","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1136\/annrheumdis-2014-205675","volume":"74","author":"A Ogdie","year":"2015","unstructured":"Ogdie, A. et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann. Rheum. Dis. 74, 326\u2013332 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"776_CR126","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1136\/annrheumdis-2020-217595","volume":"79","author":"SHM Lam","year":"2020","unstructured":"Lam, S. H. M. et al. DAPSA, carotid plaque and cardiovascular events in psoriatic arthritis: a longitudinal study. Ann. Rheum. Dis. 79, 1320\u20131326 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"776_CR127","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.jaad.2017.06.028","volume":"77","author":"A Egeberg","year":"2017","unstructured":"Egeberg, A. et al. The relationship between duration of psoriasis, vascular inflammation, and cardiovascular events. J. Am. Acad. Dermatol. 77, 650\u2013656.e3 (2017).","journal-title":"J. Am. Acad. Dermatol."},{"key":"776_CR128","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/acr.22926","volume":"69","author":"A Polachek","year":"2017","unstructured":"Polachek, A. et al. Risk of cardiovascular morbidity in patients with psoriatic arthritis: a meta-analysis of observational studies. Arthritis Care Res. 69, 67\u201374 (2017).","journal-title":"Arthritis Care Res."},{"key":"776_CR129","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1136\/annrheumdis-2011-201194","volume":"72","author":"A Jamnitski","year":"2013","unstructured":"Jamnitski, A. et al. Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Ann. Rheum. Dis. 72, 211\u2013216 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"776_CR130","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1002\/acr.23171","volume":"69","author":"H Radner","year":"2017","unstructured":"Radner, H. et al. Incidence and prevalence of cardiovascular risk factors among patients with rheumatoid arthritis, psoriasis, or psoriatic arthritis. Arthritis Care Res. 69, 1510\u20131518 (2017).","journal-title":"Arthritis Care Res."},{"key":"776_CR131","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1093\/rheumatology\/key286","volume":"58","author":"R Charlton","year":"2019","unstructured":"Charlton, R. et al. Risk of type 2 diabetes and cardiovascular disease in an incident cohort of people with psoriatic arthritis: a population-based cohort study. Rheumatology 58, 144\u2013148 (2019).","journal-title":"Rheumatology"},{"key":"776_CR132","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3389\/fimmu.2018.00139","volume":"9","author":"RA Kolliker Frers","year":"2018","unstructured":"Kolliker Frers, R. A. et al. Immune-mediated inflammation promotes subclinical atherosclerosis in recent-onset psoriatic arthritis patients without conventional cardiovascular risk factors. Front. Immunol. 9, 139 (2018).","journal-title":"Front. Immunol."},{"key":"776_CR133","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1002\/art.40389","volume":"70","author":"A Szentpetery","year":"2018","unstructured":"Szentpetery, A. et al. Higher coronary plaque burden in psoriatic arthritis is independent of metabolic syndrome and associated with underlying disease severity. Arthritis Rheumatol. 70, 396\u2013407 (2018).","journal-title":"Arthritis Rheumatol."},{"key":"776_CR134","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1161\/CIRCULATIONAHA.116.026859","volume":"136","author":"JB Lerman","year":"2017","unstructured":"Lerman, J. B. et al. Coronary plaque characterization in psoriasis reveals high-risk features that improve after treatment in a prospective observational study. Circulation 136, 263\u2013276 (2017).","journal-title":"Circulation"},{"key":"776_CR135","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1111\/jdv.14951","volume":"32","author":"JJ Wu","year":"2018","unstructured":"Wu, J. J. et al. Anti-inflammatory therapy with tumour necrosis factor inhibitors is associated with reduced risk of major adverse cardiovascular events in psoriasis. J. Eur. Acad. Dermatol. Venereol. 32, 1320\u20131326 (2018).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"776_CR136","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1002\/art.40366","volume":"70","author":"L Eder","year":"2018","unstructured":"Eder, L. et al. Association of tumor necrosis factor inhibitor treatment with reduced indices of subclinical atherosclerosis in patients with psoriatic disease. Arthritis Rheumatol. 70, 408\u2013416 (2018).","journal-title":"Arthritis Rheumatol."},{"key":"776_CR137","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1093\/cvr\/cvz009","volume":"115","author":"YA Elnabawi","year":"2019","unstructured":"Elnabawi, Y. A. et al. Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study. Cardiovasc. Res. 115, 721\u2013728 (2019).","journal-title":"Cardiovasc. Res."},{"key":"776_CR138","first-page":"559","volume":"3","author":"H Koebner","year":"1876","unstructured":"Koebner, H. Zur aetilologie der psoriasis. Vjschr Dermatol. 3, 559 (1876).","journal-title":"Vjschr Dermatol."},{"key":"776_CR139","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1111\/1346-8138.15507","volume":"47","author":"K Furue","year":"2020","unstructured":"Furue, K. et al. Pathogenic implication of epidermal scratch injury in psoriasis and atopic dermatitis. J. Dermatol. 47, 979\u2013988 (2020).","journal-title":"J. Dermatol."},{"key":"776_CR140","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/j.1365-4362.1982.tb02070.x","volume":"21","author":"RA Miller","year":"1982","unstructured":"Miller, R. A. The Koebner phenomenon. Int. J. Dermatol. 21, 192\u2013197 (1982).","journal-title":"Int. J. Dermatol."},{"key":"776_CR141","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1001\/archderm.1972.01620140101033","volume":"106","author":"JO Kirschbaum","year":"1972","unstructured":"Kirschbaum, J. O. Koebner phenomenon following acupuncture. Arch. Dermatol. 106, 767 (1972).","journal-title":"Arch. Dermatol."},{"key":"776_CR142","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1111\/jdv.15975","volume":"34","author":"C Grodner","year":"2020","unstructured":"Grodner, C. et al. Tattoo complications in treated and non-treated psoriatic patients. J. Eur. Acad. Dermatol. Venereol. 34, 888\u2013896 (2020).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"776_CR143","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.3899\/jrheum.201123","volume":"48","author":"S Belman","year":"2021","unstructured":"Belman, S. et al. Psoriasis characteristics for the early detection of psoriatic arthritis. J. Rheumatol. 48, 1559\u20131565 (2021).","journal-title":"J. Rheumatol."},{"key":"776_CR144","doi-asserted-by":"publisher","first-page":"61ra90","DOI":"10.1126\/scitranslmed.3001108","volume":"2","author":"R Wolf","year":"2010","unstructured":"Wolf, R. et al. Gene from a psoriasis susceptibility locus primes the skin for inflammation. Sci. Transl. Med. 2, 61ra90 (2010).","journal-title":"Sci. Transl. Med."},{"key":"776_CR145","doi-asserted-by":"publisher","first-page":"961","DOI":"10.2353\/ajpath.2008.070710","volume":"172","author":"SP Raychaudhuri","year":"2008","unstructured":"Raychaudhuri, S. P. et al. Revisiting the Koebner phenomenon: role of NGF and its receptor system in the pathogenesis of psoriasis. Am. J. Pathol. 172, 961\u2013971 (2008).","journal-title":"Am. J. Pathol."},{"key":"776_CR146","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.1172\/JCI63451","volume":"122","author":"L Tortola","year":"2012","unstructured":"Tortola, L. et al. Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk. J. Clin. Invest. 122, 3965\u20133976 (2012).","journal-title":"J. Clin. Invest."},{"key":"776_CR147","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.immuni.2016.06.021","volume":"45","author":"LJ Zhang","year":"2016","unstructured":"Zhang, L. J. et al. Antimicrobial peptide LL37 and MAVS signaling drive interferon-\u03b2 production by epidermal keratinocytes during skin injury. Immunity 45, 119\u2013130 (2016).","journal-title":"Immunity"},{"key":"776_CR148","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1002\/art.39494","volume":"68","author":"L Eder","year":"2016","unstructured":"Eder, L. et al. The incidence and risk factors for psoriatic arthritis in patients with psoriasis: a prospective cohort study. Arthritis Rheumatol. 68, 915\u2013923 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"776_CR149","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1136\/annrheumdis-2016-209334","volume":"76","author":"SM Thorarensen","year":"2017","unstructured":"Thorarensen, S. M. et al. Physical trauma recorded in primary care is associated with the onset of psoriatic arthritis among patients with psoriasis. Ann. Rheum. Dis. 76, 521\u2013525 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"776_CR150","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMra1505557","volume":"376","author":"CT Ritchlin","year":"2017","unstructured":"Ritchlin, C. T., Colbert, R. A. & Gladmann, D. D. Psoriatic arthritis. N. Engl. J. Med. 376, 957\u2013970 (2017).","journal-title":"N. Engl. J. Med."},{"key":"776_CR151","doi-asserted-by":"publisher","DOI":"10.1038\/srep27149","volume":"6","author":"NL Millar","year":"2016","unstructured":"Millar, N. L. et al. IL-17A mediates inflammatory and tissue remodelling events in early human tendinopathy. Sci. Rep. 6, 27149 (2016).","journal-title":"Sci. Rep."},{"key":"776_CR152","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/s41584-019-0364-x","volume":"16","author":"E Gracey","year":"2020","unstructured":"Gracey, E. et al. Tendon and ligament mechanical loading in the pathogenesis of inflammatory arthritis. Nat. Rev. Rheumatol. 16, 193\u2013207 (2020).","journal-title":"Nat. Rev. Rheumatol."},{"key":"776_CR153","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jor.22750","volume":"33","author":"K Otabe","year":"2015","unstructured":"Otabe, K. et al. Transcription factor Mohawk controls tenogenic differentiation of bone marrow mesenchymal stem cells in vitro and in vivo. J. Orthop. Res. 33, 1\u20138 (2015).","journal-title":"J. Orthop. Res."},{"key":"776_CR154","doi-asserted-by":"publisher","DOI":"10.1038\/srep45010","volume":"7","author":"Y Yoshimoto","year":"2017","unstructured":"Yoshimoto, Y. et al. Scleraxis is required for maturation of tissue domains for proper integration of the musculoskeletal system. Sci. Rep. 7, 45010 (2017).","journal-title":"Sci. Rep."},{"key":"776_CR155","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06933-4","volume":"9","author":"I Cambr\u00e9","year":"2018","unstructured":"Cambr\u00e9, I. et al. Mechanical strain determines the site-specific localization of inflammation and tissue damage in arthritis. Nat. Commun. 9, 4613 (2018).","journal-title":"Nat. Commun."},{"key":"776_CR156","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1136\/annrheumdis-2018-214627","volume":"78","author":"I Cambr\u00e9","year":"2019","unstructured":"Cambr\u00e9, I. et al. Running promotes chronicity of arthritis by local modulation of complement activators and impairing T regulatory feedback loops. Ann. Rheum. Dis. 78, 787\u2013795 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"776_CR157","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1136\/annrheumdis-2013-203643","volume":"73","author":"P Jacques","year":"2014","unstructured":"Jacques, P. et al. Proof of concept: enthesitis and new bone formation in spondyloarthritis are driven by mechanical strain and stromal cells. Ann. Rheum. Dis. 73, 437\u2013445 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"776_CR158","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1126\/science.1381521","volume":"257","author":"AB Malmberg","year":"1992","unstructured":"Malmberg, A. B. & Yaksh, T. L. Hyperalgesia mediated by spinal glutamate or substance P receptor blocked by spinal cyclooxygenase inhibition. Science 257, 1276\u20131279 (1992).","journal-title":"Science"},{"key":"776_CR159","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1182\/blood-2002-11-3400","volume":"102","author":"R Slacedo","year":"2003","unstructured":"Slacedo, R. et al. Angiogenic effects of prostaglandin E2 are mediated by up-regulation of CXCR4 on human microvascular endothelial cells. Blood 102, 1966\u20131977 (2003).","journal-title":"Blood"},{"key":"776_CR160","doi-asserted-by":"publisher","first-page":"3696","DOI":"10.1182\/blood-2008-05-155408","volume":"112","author":"C Chizzolini","year":"2008","unstructured":"Chizzolini, C. et al. Prostaglandin E2 synergistically with interleukin-23 favors human Th17 expansion. Blood 112, 3696\u20133703 (2008).","journal-title":"Blood"},{"key":"776_CR161","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1056\/NEJMra1909094","volume":"385","author":"G Schett","year":"2021","unstructured":"Schett, G., McInnes, I. B. & Neurath, M. F. Reframing immune-mediated inflammatory diseases through signature cytokine hubs. N. Engl. J. Med. 385, 628\u2013639 (2021).","journal-title":"N. Engl. J. Med."},{"key":"776_CR162","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","volume":"395","author":"A Deodhar","year":"2020","unstructured":"Deodhar, A. et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF\u03b1 inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet 395, 1115\u20131125 (2020).","journal-title":"Lancet"},{"key":"776_CR163","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","volume":"382","author":"IB McInnes","year":"2013","unstructured":"McInnes, I. B. et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 382, 780\u2013789 (2013).","journal-title":"Lancet"},{"key":"776_CR164","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1038\/nm.2817","volume":"18","author":"JP Sherlock","year":"2012","unstructured":"Sherlock, J. P. et al. IL-23 induces spondyloarthropathy by acting on ROR-\u03b3t+ CD3+CD4\u2212CD8\u2212 entheseal resident T cells. Nat. Med. 18, 1069\u20131076 (2012).","journal-title":"Nat. Med."},{"key":"776_CR165","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1136\/annrheumdis-2020-218186","volume":"80","author":"A Nerviani","year":"2021","unstructured":"Nerviani, A. et al. IL-23 skin and joint profiling in psoriatic arthritis: novel perspectives in understanding clinical responses to IL-23 inhibitors. Ann. Rheum. Dis. 80, 591\u2013597 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"776_CR166","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1136\/annrheumdis-2018-214138","volume":"78","author":"SM Wade","year":"2019","unstructured":"Wade, S. M. et al. Association of synovial tissue polyfunctional T-cells with DAPSA in psoriatic arthritis. Ann. Rheum. Dis. 78, 350\u2013354 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"776_CR167","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1002\/art.39732","volume":"68","author":"A Reinhardt","year":"2016","unstructured":"Reinhardt, A. et al. Interleukin-23-dependent \u03b3\/\u03b4 T cells produce interleukin-17 and accumulate in the enthesis, aortic valve, and ciliary body in mice. Arthritis Rheumatol. 68, 2476\u20132486 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"776_CR168","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1136\/annrheumdis-2020-217309","volume":"79","author":"A Watad","year":"2020","unstructured":"Watad, A. et al. Normal human enthesis harbours conventional CD4+ and CD8+ T cells with regulatory features and inducible IL-17A and TNF expression. Ann. Rheum. Dis. 79, 1044\u20131054 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"776_CR169","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1002\/art.40150","volume":"69","author":"RJ Cuthbert","year":"2017","unstructured":"Cuthbert, R. J. et al. Group 3 innate lymphoid cells in human enthesis. Arthritis Rheumatol. 69, 1816\u20131822 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"776_CR170","doi-asserted-by":"publisher","first-page":"154855","DOI":"10.1016\/j.cyto.2019.154855","volume":"125","author":"SK Raychaudhuri","year":"2020","unstructured":"Raychaudhuri, S. K., Abria, C., Mitra, A. & Raychaudhuri, S. P. Functional significance of MAIT cells in psoriatic arthritis. Cytokine 125, 154855 (2020).","journal-title":"Cytokine"},{"key":"776_CR171","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.semarthrit.2018.05.011","volume":"48","author":"EG Araujo","year":"2019","unstructured":"Araujo, E. G. et al. Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study. Semin. Arthritis Rheum. 48, 632\u2013637 (2019).","journal-title":"Semin. Arthritis Rheum."},{"key":"776_CR172","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1002\/art.40778","volume":"71","author":"L Savage","year":"2019","unstructured":"Savage, L. et al. Regression of peripheral subclinical enthesopathy in therapy-naive patients treated with ustekinumab for moderate-to-severe chronic plaque psoriasis: a fifty-two-week, prospective, open-label feasibility study. Arthritis Rheumatol. 71, 626\u2013631 (2019).","journal-title":"Arthritis Rheumatol."},{"key":"776_CR173","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1136\/annrheumdis-2018-213328","volume":"77","author":"D Baeten","year":"2018","unstructured":"Baeten, D. et al. Risankizuma, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. Ann. Rheum. Dis. 77, 1295\u20131302 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"776_CR174","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1136\/annrheumdis-2019-215210","volume":"78","author":"RJ Cuthert","year":"2019","unstructured":"Cuthert, R. J. et al. Evidence that tissue resident human enthesis \u03b3\u03b4T cells can produce IL-17A independently of IL-23R transcript expression. Ann. Rheum. Dis. 78, 1559\u20131565 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"776_CR175","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","volume":"373","author":"P Mease","year":"2015","unstructured":"Mease, P. et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N. Engl. J. Med. 373, 1329\u20131339 (2015).","journal-title":"N. Engl. J. Med."},{"key":"776_CR176","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","volume":"76","author":"P Mease","year":"2017","unstructured":"Mease, P. et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann. Rheum. Dis. 76, 79\u201387 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"776_CR177","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/S0140-6736(19)33161-7","volume":"395","author":"CT Ritchlin","year":"2020","unstructured":"Ritchlin, C. T. et al. Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial. Lancet 395, 427\u2013440 (2020).","journal-title":"Lancet"},{"key":"776_CR178","doi-asserted-by":"publisher","first-page":"490","DOI":"10.4049\/jimmunol.1100123","volume":"187","author":"AM Lin","year":"2011","unstructured":"Lin, A. M. et al. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J. Immunol. 187, 490\u2013500 (2011).","journal-title":"J. Immunol."},{"key":"776_CR179","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1084\/jem.194.4.519","volume":"194","author":"P Ye","year":"2001","unstructured":"Ye, P. et al. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J. Exp. Med. 194, 519\u2013527 (2001).","journal-title":"J. Exp. Med."},{"key":"776_CR180","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.4049\/jimmunol.1300274","volume":"191","author":"SMJ Paulissen","year":"2013","unstructured":"Paulissen, S. M. J. et al. Synovial fibroblasts directly induce Th17 pathogenicity via the cyclooxygenase\/prostaglandin E2 pathway, independent of IL-23. J. Immunol. 191, 1364\u20131372 (2013).","journal-title":"J. Immunol."},{"key":"776_CR181","doi-asserted-by":"publisher","first-page":"4125","DOI":"10.1002\/art.37695","volume":"64","author":"F Richter","year":"2012","unstructured":"Richter, F. et al. Interleukin-17 sensitizes joint nociceptors to mechanical stimuli and contributes to arthritic pain through neuronal interleukin-17 receptors in rodents. Arthritis Rheum. 64, 4125\u20134134 (2012).","journal-title":"Arthritis Rheum."},{"key":"776_CR182","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13075-018-1610-3","volume":"20","author":"IB McInnes","year":"2018","unstructured":"McInnes, I. B. et al. Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study. Arthritis Res. Ther. 20, 113 (2018).","journal-title":"Arthritis Res. Ther."},{"key":"776_CR183","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/s41577-020-0285-6","volume":"20","author":"MG Netea","year":"2020","unstructured":"Netea, M. G. et al. Defining trained immunity and its role in health and disease. Nat. Rev. Immunol. 20, 375\u2013388 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"776_CR184","doi-asserted-by":"crossref","first-page":"4102","DOI":"10.4049\/jimmunol.152.8.4102","volume":"152","author":"AL Van Dervort","year":"1994","unstructured":"Van Dervort, A. L. et al. Nitric oxide regulates endotoxin-induced TNF-alpha production by human neutrophils. J. Immunol. 152, 4102\u20134109 (1994).","journal-title":"J. Immunol."},{"key":"776_CR185","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1136\/ard.2004.032268","volume":"64","author":"C Antoni","year":"2005","unstructured":"Antoni, C. et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann. Rheum. Dis. 64, 1150\u20131157 (2005).","journal-title":"Ann. Rheum. Dis."},{"key":"776_CR186","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1136\/annrheumdis-2013-205056","volume":"73","author":"A Kavanaugh","year":"2014","unstructured":"Kavanaugh, A. et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann. Rheum. Dis. 73, 1020\u20131026 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"776_CR187","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","volume":"377","author":"P Mease","year":"2017","unstructured":"Mease, P. et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N. Engl. J. Med. 377, 1537\u201311550 (2017).","journal-title":"N. Engl. J. Med."},{"key":"776_CR188","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1056\/NEJMoa2022516","volume":"384","author":"IB McInnes","year":"2021","unstructured":"McInnes, I. B. et al. Trial of upadacitinib and adalimumab for psoriatic arthritis. N. Engl. J. Med. 384, 1227\u20131239 (2021).","journal-title":"N. Engl. J. Med."},{"key":"776_CR189","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1007\/s10067-015-3002-2","volume":"34","author":"U Fiocco","year":"2015","unstructured":"Fiocco, U. et al. Transcriptional network profile on synovial fluid T cells in psoriatic arthritis. Clin. Rheumatol. 34, 1571\u20131580 (2015).","journal-title":"Clin. Rheumatol."},{"key":"776_CR190","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s12026-013-8481-0","volume":"58","author":"U Fiocco","year":"2014","unstructured":"Fiocco, U. et al. JAK\/STAT\/PKC\u03b4 molecular pathways in synovial fluid T lymphocytes reflect the in vivo T helper-17 expansion in psoriatic arthritis. Immunol. Res. 58, 61\u201369 (2014).","journal-title":"Immunol. Res."},{"key":"776_CR191","doi-asserted-by":"publisher","first-page":"672461","DOI":"10.3389\/fimmu.2021.672461","volume":"12","author":"A O\u2019Brien","year":"2021","unstructured":"O\u2019Brien, A. et al. Targeting JAK-STAT signalling alters PsA synovial fibroblast pro-inflammatory and metabolic function. Front. Immunol. 12, 672461 (2021).","journal-title":"Front. Immunol."},{"key":"776_CR192","first-page":"1117","volume":"26","author":"P Costello","year":"1999","unstructured":"Costello, P., Bresnihan, B., O\u2019Farrelly, C. & FitzGerald, O. Predominance of CD8+ T lymphocytes in psoriatic arthritis. J. Rheumatol. 26, 1117\u20131124 (1999).","journal-title":"J. Rheumatol."},{"key":"776_CR193","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-47310-5","volume":"9","author":"M Diani","year":"2019","unstructured":"Diani, M. et al. Increased frequency of activated CD8+ T cell effectors in patients with psoriatic arthritis. Sci. Rep. 9, 10870 (2019).","journal-title":"Sci. Rep."},{"key":"776_CR194","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13075-020-2111-8","volume":"22","author":"MV Sokolova","year":"2020","unstructured":"Sokolova, M. V. et al. A set of serum markers detecting systemic inflammation in psoriatic skin, entheseal, and joint disease in the absence of C-reactive protein and its link to clinical disease manifestations. Arthritis Res. Ther. 22, 26 (2020).","journal-title":"Arthritis Res. Ther."},{"key":"776_CR195","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1136\/annrheumdis-2021-220280","volume":"80","author":"N Yager","year":"2021","unstructured":"Yager, N. et al. Ex vivo mass cytometry analysis reveals a profound myeloid proinflammatory signature in psoriatic arthritis synovial fluid. Ann. Rheum. Dis. 80, 1559\u20131567 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"776_CR196","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1136\/annrheumdis-2013-204858","volume":"74","author":"M Haroon","year":"2015","unstructured":"Haroon, M., Gallagher, P. & FitzGerald, O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann. Rheum. Dis. 74, 1045\u20131050 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"776_CR197","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1002\/acr2.11196","volume":"2","author":"AM Liphardt","year":"2020","unstructured":"Liphardt, A. M. et al. Similar impact of psoriatic arthritis and rheumatoid arthritis on objective and subjective parameters of hand function. ACR Open Rheumatol. 2, 734\u2013740 (2020).","journal-title":"ACR Open Rheumatol."},{"key":"776_CR198","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1136\/annrheumdis-2014-206347","volume":"75","author":"D Simon","year":"2016","unstructured":"Simon, D. et al. Analysis of periarticular bone changes in patients with cutaneous psoriasis without associated psoriatic arthritis. Ann. Rheum. Dis. 75, 660\u2013666 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"776_CR199","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/art.41239","volume":"74","author":"D Simon","year":"2020","unstructured":"Simon, D. et al. Structural entheseal lesions in patients with psoriasis are associated with an increased risk of progression to psoriatic arthritis. Arthritis Rheumatol. 74, 253\u2013262 (2020).","journal-title":"Arthritis Rheumatol."},{"key":"776_CR200","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s13075-018-1691-z","volume":"20","author":"D Simon","year":"2018","unstructured":"Simon, D. et al. Simultaneous quantification of bone erosions and enthesiophytes in the joints of patients with psoriasis or psoriatic arthritis \u2014 effects of age and disease duration. Arthritis Res. Ther. 20, 203 (2018).","journal-title":"Arthritis Res. Ther."},{"key":"776_CR201","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1172\/JCI0215681","volume":"109","author":"X Zhang","year":"2002","unstructured":"Zhang, X. et al. Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J. Clin. Invest. 109, 1405\u20131415 (2002).","journal-title":"J. Clin. Invest."},{"key":"776_CR202","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10928","volume":"7","author":"T Ono","year":"2016","unstructured":"Ono, T. et al. IL-17-producing \u03b3\u03b4 T cells enhance bone regeneration. Nat. Commun. 7, 10928 (2016).","journal-title":"Nat. Commun."},{"key":"776_CR203","first-page":"488","volume":"56","author":"AA El-Zayadi","year":"2017","unstructured":"El-Zayadi, A. A. et al. Interleukin-22 drives the proliferation, migration and osteogenic differentiation of mesenchymal stem cells: a novel cytokine that could contribute to new bone formation in spondyloarthropathies. Rheumatology 56, 488\u2013493 (2017).","journal-title":"Rheumatology"},{"key":"776_CR204","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1002\/art.33504","volume":"64","author":"MM Matzelle","year":"2012","unstructured":"Matzelle, M. M. et al. Resolution of inflammation induces osteoblast function and regulates the Wnt signaling pathway. Arthritis Rheum. 64, 1540\u20131550 (2012).","journal-title":"Arthritis Rheum."},{"key":"776_CR205","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1002\/art.38794","volume":"66","author":"S Finzel","year":"2014","unstructured":"Finzel, S. et al. Inflammatory bone spur formation in psoriatic arthritis is different from bone spur formation in hand osteoarthritis. Arthritis Rheumatol. 66, 2968\u20132975 (2014).","journal-title":"Arthritis Rheumatol."},{"key":"776_CR206","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1172\/JCI200316069","volume":"111","author":"CT Ritchlin","year":"2003","unstructured":"Ritchlin, C. T. et al. Mechanisms of TNF-\u03b1- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J. Clin. Invest. 111, 821\u2013831 (2003).","journal-title":"J. Clin. Invest."},{"key":"776_CR207","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1172\/JCI11176","volume":"106","author":"J Lam","year":"2000","unstructured":"Lam, J. et al. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J. Clin. Invest. 106, 1481\u20131488 (2000).","journal-title":"J. Clin. Invest."},{"key":"776_CR208","doi-asserted-by":"publisher","first-page":"R29","DOI":"10.1186\/ar2936","volume":"12","author":"IE Adamopoulos","year":"2010","unstructured":"Adamopoulos, I. E. et al. Interleukin-17A upregulates receptor activator of NF-kappaB on osteoclast precursors. Arthritis Res. Ther. 12, R29 (2010).","journal-title":"Arthritis Res. Ther."},{"key":"776_CR209","doi-asserted-by":"publisher","first-page":"330ra337","DOI":"10.1126\/scitranslmed.aad8996","volume":"8","author":"O Uluckan","year":"2016","unstructured":"Uluckan, O. et al. Chronic skin inflammation leads to bone loss by IL-17-mediated inhibition of Wnt signaling in osteoblasts. Sci. Transl. Med. 8, 330ra337 (2016).","journal-title":"Sci. Transl. Med."},{"key":"776_CR210","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s13075-019-1938-3","volume":"21","author":"D Simon","year":"2019","unstructured":"Simon, D. et al. Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patients. Arthritis Res. Ther. 21, 162 (2019).","journal-title":"Arthritis Res. Ther."},{"key":"776_CR211","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1093\/rheumatology\/key199","volume":"57","author":"G DeMarco","year":"2018","unstructured":"DeMarco, G. et al. Combined inhibition of tumor necrosis factor-alpha and interleukin12\/23 for long-standing, refractory psoriatic disease: a differential role for cytokine pathways. Rheumatology 57, 2053\u20132055 (2018).","journal-title":"Rheumatology"},{"key":"776_CR212","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1111\/j.1346-8138.2012.01577.x","volume":"39","author":"LJ Zhu","year":"2012","unstructured":"Zhu, L. J., Zhu, C. Y. & Fan, Y. M. Alcohol consumption and psoriatic risk: a meta-analysis of case-control studies. J. Dermatol. 39, 770\u2013773 (2012).","journal-title":"J. Dermatol."},{"key":"776_CR213","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1111\/bjd.18227","volume":"182","author":"A Green","year":"2020","unstructured":"Green, A. et al. Modifiable risk factors and the development of psoriatic arthritis in people with psoriasis. Br. J. Dermatol. 182, 714\u2013720 (2020).","journal-title":"Br. J. Dermatol."},{"key":"776_CR214","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1136\/annrheumdis-2017-211625","volume":"77","author":"US Nguyen","year":"2018","unstructured":"Nguyen, U. S. et al. The smoking paradox in the development of psoriatic arthritis among psoriasis patients \u2014 a population-based study. Ann. Rheum. Dis. 77, 119\u2013123 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"776_CR215","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1136\/annrheumdis-2021-219961","volume":"81","author":"P Gisondi","year":"2022","unstructured":"Gisondi, P. et al. Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis. Ann. Rheum. Dis. 81, 68\u201373 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"776_CR216","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s13075-019-1957-0","volume":"21","author":"E Kampylafka","year":"2019","unstructured":"Kampylafka, E. et al. Disease interception with interleukin-17 inhibition in high-risk psoriasis patients with subclinical joint inflammation-data from the prospective IVEPSA study. Arthritis Res. Ther. 21, 178 (2019).","journal-title":"Arthritis Res. Ther."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41584-022-00776-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-022-00776-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-022-00776-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T08:40:02Z","timestamp":1675500002000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-022-00776-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,5]]},"references-count":216,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["776"],"URL":"https:\/\/doi.org\/10.1038\/s41584-022-00776-6","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,5]]},"assertion":[{"value":"29 March 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}